HHS Finally Ends Long-Running COVID Emergency Drug Rules
Published Date: 7/2/2026
Notice
Summary
The U.S. Department of Health and Human Services is ending the special emergency rules that allowed quick use of COVID-19 drugs and vaccines. This change affects companies, healthcare workers, and patients who relied on these emergency approvals. The emergency use authorization will officially stop on June 29, 2027, giving everyone time to adjust without sudden disruptions or extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
EUA Declaration Ends June 29, 2027
The special HHS declaration that allowed Emergency Use Authorizations (EUAs) for COVID-19 drugs and biological products will terminate effective June 29, 2027. This ends the legal basis for issuing new EUAs under that declaration and affects companies, healthcare workers, and patients who relied on EUA-authorized products.
12-Month Transition: No New EUA Reviews
HHS is providing 12 months' advance notice and FDA has decided it will decline to review or process any new EUA requests for COVID-19 drugs or biological products during that 12-month transition period. FDA will only review EUA amendments during that period if they are necessary to protect public health (for example, labeling changes for drug interactions or updated variant susceptibility data).
Path to Full Approval and Access Options
FDA is encouraging sponsors of EUA products to seek full approval by submitting New Drug Applications (NDAs) or Biologics License Applications (BLAs), and says the 12-month transition period is a reasonable time for sponsors to generate data to support such submissions. If a gap exists between the end of an EUA and FDA approval, sponsors can work with FDA to maintain access through clinical trials and expanded access protocols, and FDA will consult with manufacturers about disposition of unapproved products.
Some COVID-19 EUAs Revoked; Products Licensed
The notice states that EUAs for COVID-19 vaccines and convalescent plasma have already been revoked and that there are now COVID-19 vaccines and convalescent plasma products licensed through traditional Biologics License Applications (BLAs). The FDA also says there are FDA-approved therapeutic options available for all ages and across the spectrum of disease.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20281, Global Benchmark for Efficient Drug Pricing (GLOBE) Model
Starting November 30, 2026, Medicare will use the new GLOBE Model to help lower the cost of certain drugs for people on Original Medicare. This model changes how drug price increases are calculated, aiming to save money for both patients and the Medicare program without cutting care quality. If you’re on Medicare Part B, expect smarter drug pricing that helps keep your healthcare affordable.
2026-20131, Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program; Correction
This correction fixes some technical mistakes in the Medicare payment rules for inpatient rehab facilities starting October 1, 2026. It mainly affects hospitals and rehab centers by clarifying how wage data and payments are calculated, ensuring fairer payment rates for fiscal year 2027. No big changes in money, but it keeps everything accurate and on track.
2026-20067, Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements; Correction
This correction fixes some technical mistakes in the FY 2027 hospice payment and wage index rules that were first published in August 2026. It mainly affects hospice providers by updating how their payments are calculated, making sure the numbers are accurate starting October 1, 2026. These changes help ensure hospices get the right payment amounts based on the latest hospital wage data.
2026-19959, Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027; Correction
This correction fixes some technical mistakes in Medicare payment rules for skilled nursing facilities starting October 1, 2026. It mainly affects how hospital data is used to calculate payments, making sure no current hospitals are wrongly excluded. These tweaks help keep Medicare payments fair and accurate for providers and patients.
2026-19946, Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions of Certain Health Information Technology Standards; Correction
This update fixes some typos and technical mistakes in the Medicare payment rules for hospitals starting October 1, 2026. It affects hospitals getting paid for patient care, making sure the payment system and quality programs run smoothly. These corrections help hospitals get the right payments and follow updated health tech standards without delays or confusion.
2026-19493, Patient Protection and Affordable Care Act; Temporary Moratoria on Certain Agent and Broker Registration To Participate in the Exchanges
Starting now, new agents and brokers without a 2026 registration can’t sign up to help people enroll in health insurance through federal exchanges for 2027. This pause helps stop fraud and protect your info while CMS improves safety rules. If you’re already registered or working with state exchanges, this doesn’t affect you.
Previous / Next Documents
Previous: 2026-13373, Termination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemic
The U.S. Department of Health and Human Services is ending the emergency use authorizations for certain COVID-19 medical devices, including tests and masks, on December 26, 2026. This change affects manufacturers, healthcare providers, and anyone using these devices, signaling a return to normal rules and regulations. No emergency use means these products will now follow regular approval processes, with no extra emergency funding involved.
Next: 2026-13376, Initiation of Five-Year (Sunset) Reviews
The U.S. Department of Commerce is kicking off its automatic five-year checkup on certain trade duties to see if they should stay or go. This affects companies importing products like ironing tables and magnesia carbon from countries like China. Starting July 2, 2026, these reviews could impact prices and trade rules, so businesses should stay alert!